ANNE SOPHIE KUBASCH
UWE PLATZBECKER

EMSCO

Let us introduce EMSCO,
the European MDS Studies coordination office, facilitating academic clinical research, education and consulting in the field of MDS across Europe.

www.emsco.eu



EMSCO

MYELODYSPLASTIC SYNDROMES



EMSCO

- **Academic clinical research**
  - Sponsor function
  - Site recruiting/feasibility
  - MDS specific eCRFs and SOPs
  - Monitoring
  - Biostatistics
- **Education**
  - Conference planning
  - Training in MDS diagnostics
- **Consulting**
  - Clinical Trial Design for MDS
  - Regulatory Consultancy
  - Feasibility Studies

As you already know, multiple MDS clinical trials are currently running across the world, especially in the EU. Both the Groupe Francophone des Myélodysplasies (GFM) and the German MDS study group (GMDS-SG) are one of the leader in conducting trials together.

Until today, clinical research is the key to medical progress und innovation. At the same time, clinical studies must meet high ethical, legal, methodical and scientific requirements followed by a high level of coordination and organisation effort to guarantee professionality. Because MDS classification and risk stratification selecting the right individual treatment option for MDS patients becomes more and more complex, EMSCO was founded at the beginning of 2013 in order to facilitate research, accelerate translation and optimize trial recruitment in MDS research.

And here we go, on behalf of the German and French MDS study groups, EMSCO is now a coordinating collaboration and partnership between scientific study groups in a European network with key contact sites in 10 European countries allowing multiple partnerships by intensifying clinical trial exchange in the EU.

MDS CENTER APP

- **Individual calculator and tables for the WHO classification**
- **Calculator for IPSS and IPSS-R scores**
- **Therapy algorithm to identify treatment options and clinical trials for a given patient**
- **Clinical trial finder**
- **Knowledge**

The services of EMSCO include the production of study designs, documentation of clinical studies, support of study participants regarding necessary documents and forms, drafting and signing of contracts and mostly the coordination of clinical studies and projects in the field of MDS. As you might have guessed, EMSCO enables to more rapid patient recruitment and increases the amount of clinical studies in the whole EU. Moreover, EMSCO organises special events such as conferences, symposia, workshops as well as strategic progress meetings for scientists and the pharmaceutical industry.

A totally new intervention, the “MDS Center App“, has been launched by our MDS team in Dresden last year, helping treating physicians to gain and maintain an overview on the clinical trial landscape in MDS. At first, the individual calculation tool for the 2016 WHO classification is guiding the physician through the different MDS parameters. For you it is interesting to know, that we have included a conversion table showing corresponding classifications between WHO 2016, WHO 2008 and FAB. Before finding the right study, calculations of IPSS, IPSS-R and CPSS-mol scores is necessary and can be easily done using the „MDS Center App“.



After all, it is most important to decide for the right treatment option: the app provides an interactive step-by-step therapy algorithm for MDS and CMML patients. Covering the given criteria, the algorithm offers the possibility to indicate ongoing clinical trials for the individual patient in the field of MDS and CMML in Germany, Austria and Switzerland. A summary page provides an overview on all listed trials, including inclusion and exclusion criteria, participating sites and current trials status. Our platform EMSCO is currently coordinating multiple clinical trials including DACOTA TRIAL, a randomized phase III study of decitabine (DAC) with or without hydroxyurea (HY) versus HY in patients with advanced proliferative CMML. The currently ongoing EUROPE TRIAL is prospective validation of a predictive model of response to romiplostim in patients with IPSS low or intermediate-1 risk MDS and thrombocytopenia. The SINTRA-REV TRIAL is a multicenter, randomized, double-blind, phase III study of Lenalidomide versus placebo in patients with low risk MDS, alteration in 5q and anemia without the need of transfusion. The currently running BERGAMO trial is a phase II study evaluating the efficacy and safety of BGB324 in patients with MDS or AML failing standard of care therapy

Thanks for sharing and see you soon at 6th Annual EMSCO Meeting from 21-22 September 2018 in Amsterdam!